Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar
Key Highlights
- ➤12 male patients comprise FDA-aligned pivotal Phase 2 efficacy population
- ➤Seven patients must meet both co-primary response criteria at 12 months
- ➤Three modified-protocol patients showed no preliminary thrombotic microangiopathy or capillary leak evidence
- ➤Six Phase 1 patients sustained cardiac improvements through approximately three to seven years
- ➤Pivotal trial dosing targeted for mid-2027; topline results expected mid-2028
Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, highlighted key findings and development milestones presented during its October 6 Danon disease investor webinar. The update outlined a defined path to completing the FDA-aligned pivotal Phase 2 trial, highlighted sustained biological activity in longer-term Phase 1 follow-up and reported encouraging initial safety observations in the first three patients treated under the modified protocol.
Get started
Create a free account to read the full story.